(LXS) LANXESS Aktiengesellschaft - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: XETRA (Germany) | Market Cap: 1.564m EUR | Total Return: -35.3% in 12m
Avg Turnover: 10.9M
Qual. Beats: 0
Rev. Trend: -93.1%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -4.1 is critical
Below Avwap Earnings
Tailwinds
No distinct edge detected
LANXESS Aktiengesellschaft is a German specialty chemicals manufacturer headquartered in Cologne. The company operates across three core segments: Consumer Protection, Specialty Additives, and Advanced Intermediates. Its portfolio includes water treatment technologies, material protection solutions, bromine derivatives, and inorganic pigments used in construction and industrial coatings.
The specialty chemicals sector is characterized by high barriers to entry due to the technical complexity of formulations and the capital-intensive nature of chemical synthesis. Unlike commodity chemical producers, LANXESS focuses on functional additives and intermediates where pricing power is often driven by specific performance characteristics rather than volume alone.
The company serves a diverse range of end-markets, including the automotive, pharmaceutical, and agricultural industries. This broad exposure helps mitigate cyclical downturns in specific sectors, though the business remain sensitive to global industrial production trends and raw material input costs.
You can further examine the companys valuation metrics and historical performance on ValueRay.
- European industrial energy costs and natural gas prices impact manufacturing margins
- Global demand for agrochemical and pharmaceutical intermediates dictates revenue growth
- High debt levels and interest rates influence corporate deleveraging progress
- Recovery in construction and automotive sectors drives specialty additive sales volumes
- Inventory destocking cycles among global chemical customers affect short-term earnings stability
| Net Income: -661.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -1.15 > 1.0 |
| NWC/Revenue: 19.89% < 20% (prev 25.99%; Δ -6.10% < -1%) |
| CFO/TA 0.05 > 3% & CFO 349.0m > Net Income -661.0m |
| Net Debt (2.28b) to EBITDA (617.0m): 3.70 < 3 |
| Current Ratio: 1.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (86.3m) vs 12m ago 0.0% < -2% |
| Gross Margin: 19.65% > 18% (prev 0.21%; Δ 1.94k% > 0.5%) |
| Asset Turnover: 63.14% > 50% (prev 66.86%; Δ -3.72% > 0%) |
| Interest Coverage Ratio: -4.07 > 6 (EBITDA TTM 617.0m / Interest Expense TTM 43.0m) |
| A: 0.14 (Total Current Assets 2.68b - Total Current Liabilities 1.59b) / Total Assets 7.75b |
| B: 0.52 (Retained Earnings 4.01b / Total Assets 7.75b) |
| C: -0.02 (EBIT TTM -175.0m / Avg Total Assets 8.63b) |
| D: 0.53 (Book Value of Equity 2.26b / Total Liabilities 4.25b) |
| Altman-Z'' = 3.03 = A |
| DSRI: 0.99 (Receivables 644.0m/760.0m, Revenue 5.45b/6.36b) |
| GMI: 1.07 (GM 19.65% / 21.07%) |
| AQI: 1.00 (AQ_t 0.39 / AQ_t-1 0.38) |
| SGI: 0.86 (Revenue 5.45b / 6.36b) |
| TATA: -0.13 (NI -661.0m - CFO 349.0m) / TA 7.75b) |
| Beneish M = -3.20 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at EUR 17.41 with a total of 578,640 shares traded.
Over the past week, the price has changed by -8.75%,
over one month by -8.99%,
over three months by -11.33% and
over the past year by -35.34%.
LANXESS Aktiengesellschaft has no consensus analysts rating.
P/E Forward = 14.5773
P/S = 0.2869
P/B = 0.3865
P/EG = 1.1165
Revenue TTM = 5.45b EUR
EBIT TTM = -175.0m EUR
EBITDA TTM = 617.0m EUR
Long Term Debt = 1.79b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 597.0m EUR (from shortTermDebt, last quarter)
Debt = 2.70b EUR (from shortLongTermDebtTotal, last quarter) + Leases 190.0m
Net Debt = 2.28b EUR (calculated: Debt 2.70b - CCE 415.0m)
Enterprise Value = 3.85b EUR (1.56b + Debt 2.70b - CCE 415.0m)
Interest Coverage Ratio = -4.07 (Ebit TTM -175.0m / Interest Expense TTM 43.0m)
EV/FCF = 113.1x (Enterprise Value 3.85b / FCF TTM 34.0m)
FCF Yield = 0.88% (FCF TTM 34.0m / Enterprise Value 3.85b)
FCF Margin = 0.62% (FCF TTM 34.0m / Revenue TTM 5.45b)
Net Margin = -12.13% (Net Income TTM -661.0m / Revenue TTM 5.45b)
Gross Margin = 19.65% ((Revenue TTM 5.45b - Cost of Revenue TTM 4.38b) / Revenue TTM)
Gross Margin QoQ = 19.01% (prev 17.98%)
Tobins Q-Ratio = 0.50 (Enterprise Value 3.85b / Total Assets 7.75b)
Interest Expense / Debt = 1.59% (Interest Expense 43.0m / Debt 2.70b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -131.2m (EBIT -175.0m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.68 (Total Current Assets 2.68b / Total Current Liabilities 1.59b)
Debt / Equity = 0.77 (Debt 2.70b / totalStockholderEquity, last quarter 3.49b)
Debt / EBITDA = 3.70 (Net Debt 2.28b / EBITDA 617.0m)
Debt / FCF = 67.15 (Net Debt 2.28b / FCF TTM 34.0m)
Total Stockholder Equity = 3.72b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.66% (Net Income -661.0m / Total Assets 7.75b)
RoE = -17.77% (Net Income TTM -661.0m / Total Stockholder Equity 3.72b)
RoCE = -3.17% (EBIT -175.0m / Capital Employed (Equity 3.72b + L.T.Debt 1.79b))
RoIC = -1.94% (negative operating profit) (NOPAT -131.2m / Invested Capital 6.75b)
WACC = 3.95% (E(1.56b)/V(4.26b) * Re(8.71%) + D(2.70b)/V(4.26b) * Rd(1.59%) * (1-Tc(0.25)))
Discount Rate = 8.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 73.10% ; FCFF base≈80.8m ; Y1≈70.9m ; Y5≈57.2m
[DCF] Fair Price = N/A (negative equity: EV 918.9m - Net Debt 2.28b = -1.36b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.22 | # QB: 0
Revenue Correlation: -93.14 | Revenue CAGR: -9.72% | SUE: -0.14 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.49 | Chg30d=+0.00% | Revisions=N/A | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.08 | Chg30d=+0.00% | Revisions=N/A | Analysts=2
EPS current Year (2026-12-31): EPS=0.75 | Chg30d=+825.07% | Revisions=-20% | GrowthEPS=-33.4% | GrowthRev=+3.2%
EPS next Year (2027-12-31): EPS=0.44 | Chg30d=+2.38% | Revisions=+43% | GrowthEPS=-41.1% | GrowthRev=+1.2%
[Analyst] Revisions Ratio: +43%